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Abstract
Background: Neglected tropical diseases, including diseases caused by trypanosomatid parasites such as Trypanosoma
brucei, cost tens of millions of disability-adjusted life-years annually. As the current treatments for African trypanosomiasis
and other similar infections are limited, new therapeutics are urgently needed. RNA Editing Ligase 1 (REL1), a protein unique
to trypanosomes and other kinetoplastids, was identified recently as a potential drug target.
Methodology/Principal Findings: Motivated by the urgent need for novel trypanocidal therapeutics, we use an ensemble-
based virtual-screening approach to discover new naphthalene-based TbREL1 inhibitors. The predicted binding modes of
the active compounds are evaluated within the context of the flexible receptor model and combined with computational
fragment mapping to determine the most likely binding mechanisms. Ultimately, four new low-micromolar inhibitors are
presented. Three of the four compounds may bind to a newly revealed cleft that represents a putative druggable site not
evident in any crystal structure.
Conclusions/Significance: Pending additional optimization, the compounds presented here may serve as precursors for
future novel therapies useful in the fight against several trypanosomatid pathogens, including human African
trypanosomiasis, a devastating disease that afflicts the vulnerable patient populations of sub-Saharan Africa.
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Introduction
Subspecies of Trypanosoma brucei (T. brucei) are the causative agents
of human African trypanosomiasis (HAT, also known as African
sleeping sickness) in sub-Saharan Africa. Neglected tropical
diseases, including parasitic trypanosomal illnesses like HAT,
Chagas disease, and leishmaniasis, are responsible for the loss of
an estimated 56.6 million disability-adjusted life-years across
several regions, particularly in the world’s poorest countries [1].
Preventative measures such as vector control are effective at
decreasing the incidence of HAT; however, given infection, the
current treatment options are not suitable on the whole,
particularly once T. brucei has infiltrated the central nervous system
[2].
First-stage treatments include pentamidine and suramin, drugs
developed more than half a century ago. Unfortunately, these
drugs have severe side effects. Pentamidine is associated with
hypoglycaemia and hypotension, while suramin is associated with
anaphylactic shock, neurotoxic signs, severe cutaneous reactions,
and renal failure [3]. The most common treatment for second-
stage HAT is melarsoprol, a highly toxic drug with a 3%–10%
fatality rate [4]. The danger of treatment is compounded by the
emergence of melarsoprol-resistant parasites, particularly in
central Africa [5]. Eflornithine, another HAT treatment, is less
toxic but only effective against the T. b. gambiense subspecies;
additionally, eflornithine is more costly to produce than melarso-
prol [6]. Given the weaknesses of current treatments, new drugs
are urgently needed.
Fortunately, recent studies of the trypanosomal editosome have
revealed several new drug targets. In trypanosomatids, mitochon-
drial gene expression includes an extra RNA-editing step. As in
other eukaryotes, mitochondrial DNA is transcribed into RNA. In
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trypanosomes and Leishmania parasites, however, a protein complex
known as the editosome makes extensive uridylate (U) insertions and
deletions following transcription, at times even doubling the length
of the original RNA sequence [7–11]. After each cycle of U addition
or deletion, a nick in the RNA remains; RNA editing ligase 1
(TbREL1; TriTrypDB ID: Tb927.10.8210), an essential enzyme in
trypanosomes [12], is one of two ATP-dependent editosome ligases
responsible for religation. As the editosome is absent in humans, the
proteins of this complex, including REL1, are potential drug targets
in all trypanosomatid pathogens.
Recently Amaro et al. identified several novel TbREL1
inhibitors. The relaxed complex scheme, a virtual-screening
methodology that accounts for full protein flexibility [13], was
used to identify five low-micromolar inhibitors from among the
compounds of the National Cancer Institute Diversity Set I [14].
Unfortunately, these TbREL1 inhibitors were ineffective against
whole-cell T. brucei, perhaps in part because they are too
hydrophilic to cross lipid membranes (unpublished work).
Motivated by both the urgent need for novel trypanocidal
therapeutics as well as the success of virtual screening against
TbREL1 in the past, we here use the relaxed complex scheme to
identify additional naphthalene-based inhibitors in hopes of finding
compounds that can kill T. brucei. To this end, online databases of
commercially available compounds were first searched for com-
pounds similar to the inhibitors previously characterized. Following
virtual screening, the most promising of these compounds were
subsequently tested experimentally, revealing four novel TbREL1
inhibitors with unique naphthalene-based scaffolds, two of which
have ALogP values that suggest reasonable lipophilicity. Analyses of
the predicted binding modes of these active compounds, performed
using an ensemble-based approach and coupled with computa-
tional fragment mapping experiments, suggest that receptor
flexibility may play an important role in ligand binding.
Methods
Online Similarity Search
To generate a library of compounds similar to the TbREL1
inhibitors characterized previously [14], we performed online
substructure searches of several databases of commercially
available compounds, including Hit2Lead (Hit2Lead.com, Chem-
Bridge), the NCI/DTP Open Chemical Repository (dtp.cancer.
gov), Sigma-Aldrich (sigmaaldrich.com), and ZINC [15]. Searches
were performed using three structures similar to the core
naphthalene scaffolds of known inhibitors: naphthalene-2-sulfonic
acid, 2-naphthoic acid, and 2-nitronaphthalene (Figure 1).
Initial Docking against the Crystal Structure
The compounds identified via online substructure searches were
each docked into a 1.20-A˚ resolution crystal structure of the
TbREL1 catalytic domain (PDB ID: 1XDN) [16] using AutoDock
4 [17]. Ligand files were processed with AutoDockTools 1.4.5 to
merge nonpolar hydrogens with parent heteroatoms and to assign
Gasteiger charges. AutoGrid affinity grids contained 86672678
points spaced 0.375 A˚ apart, centered on the TbREL1 active site,
the ATP-binding pocket. Grid files were created for the following
ligand atom types: A (aromatic carbon), C, F, I, N, NA (hydrogen-
bond accepting N), Cl, OA (hydrogen-bond accepting O), P, S, SA
(hydrogen-bond accepting S), Br, HD (hydrogen-bond hydrogen),
and e (electrostatic).
AutoDock parameters similar to those published previously by
Amaro et al. [14] were used: population size 200; 5,000,000
evaluations; 27,000 generations; 100 runs; and cluster tolerance of
2.0 A˚. All other AutoDock parameters were set to the default
values. The correct docked pose was judged to be the lowest-
energy pose of the most populated cluster.
MD Simulation
With the intent of rescoring the top hits from the initial crystal-
structure screen in a way that accounts for full protein flexibility,
we drew upon a previous study of TbREL1 molecular motions
[18]. In brief, molecular dynamics (MD) simulations of TbREL1
were performed using NAMD 2.6 [19]. Four hundred receptor
conformations were extracted from the MD simulations, one every
50 ps. QR factorization [20] was used to eliminate conformational
redundancy, thereby reducing the number of representative
structures from 400 to 33 [14]. These 33 TbREL1 structures are
said to constitute an ensemble representative of the many protein
conformations sampled during the MD simulation.
Ensemble-Based Virtual Screening with the Relaxed
Complex Scheme
The relaxed complex scheme (RCS) was subsequently used to
rescore the top compounds from the initial crystal-structure screen
[13]. AutoDock was used to dock each of the top inhibitors into
the 33 protein conformations of the receptor ensemble using the
same docking parameters described above. The ensemble-average
binding energy of each ligand was computed by taking the simple
mean, and the ligands with the best mean predicted binding
energy were subsequently tested experimentally.
RMSD Clustering
To partition the ATP-bound trajectory [18] into a set of
structures representing regions of decreasing conformational
population density, RMSD clustering, distinct from the QR
factorization described above, was performed [21–23] as imple-
mented in the rmsdmat2 and cluster2 programs of the GRO-
MOS++ analysis software [24]. Four hundred receptor confor-
mations were extracted from the 20 ns ATP-bound MD
trajectory, one every 50 ps. Clustering was performed on a subset
of 24 residues that line the ATP binding cleft: 87–90, 155–162,
207–209, 283–287, and 305–308. These residues constitute the 5
Author Summary
African sleeping sickness is a devastating disease that
plagues sub-Saharan Africa. Neglected tropical diseases
like African sleeping sickness cause significant death and
suffering in the world’s poorest countries. Current
treatments for African sleeping sickness either have high
costs, terrible side effects, or limited effectiveness.
Consequently, new medicines are urgently needed. RNA
editing ligase 1 is an important protein critical for the
survival of Trypanosoma brucei, the unicellular parasite that
causes African sleeping sickness. In this paper, we describe
our recent efforts to use advanced computer techniques to
identify chemicals predicted to prevent RNA editing ligase
1 from functioning properly. We subsequently tested our
predicted chemicals and confirmed that a number of them
inhibited the protein’s function. Additionally, one of the
chemicals was effective at stopping the growth of the
parasite in culture. Although substantial work remains to
be done in order to optimize these chemicals so they are
effective and safe to use in human patients, the
identification of these parasite-killing compounds is
nevertheless a valuable step towards finding a better cure
for this devastating disease.
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conserved motifs of the nucleotidyltransferase superfamily [25,26]
to which TbREL1 belongs. The trajectory frames were first aligned
by minimizing the RMSD between the alpha carbons of the 24-
residue subset of each frame and the corresponding alpha carbons
of the first frame. This least-squares alignment removed external
translational and rotational motion so that subsequent RMSD
calculations could focus on the internal conformational variability
of the 24-residue subset. After varying the RMSD similarity
criterion from 0.06 to 0.12 A˚, a value of 0.085 A˚ was chosen, as
this cutoff produced 8 clusters of protein conformations. The three
most populated clusters comprised 93.5% of the trajectory.
Computational Fragment Mapping
Computational fragment mapping (FTMap, http://ftmap.bu.
edu) was utilized to identify druggable regions on the surface of
TbREL1. The FTMap algorithm [27] determines the energetically
favorable binding regions of sixteen fragments along a protein
surface (Figure S1) via the following steps: (1) rigid body docking of
fragments using a fast Fourier transform approach, (2) minimiza-
tion and rescoring of fragment-protein complexes, (3) clustering
and ranking of low-energy fragment-protein complexes, and (4)
determination of consensus sites. Consensus sites are regions of the
protein surface where low-energy fragment clusters of multiple
fragment types co-localize; in previous studies using FTMap and
its predecessor CSMap [28], highly populated consensus sites were
shown to correlate strongly with ligand binding hot spots identified
via biophysical methods [27,29,30].
Experimental Validation
The top ranked compounds from the relaxed complex screen
were obtained for testing in experimental assays. Compounds were
provided by the Developmental Therapeutic Program at the
National Cancer Institutes (NCI) of Health, Hit2Lead.com, and
Sigma-Aldrich (Table S1). Compounds V1, V2, and V3 (Figure 1)
were provided by the NCI, and compound V4 was purchased
from Sigma. All compounds were dissolved in DMSO or DMSO/
H2O.
The protocols for recombinant TbREL1 expression, purifica-
tion, and assaying have been described previously [14]. In brief,
recombinant full-length TbREL1 was expressed in Sf9 insect cells
after infection with recombinant baculovirus and purified via a C-
terminal tandem affinity purification (TAP) tag. To measure
enzyme inhibition, 0.1 pmol TbREL1 was incubated with 1.8 mCi
(30 nM) [a-32P]ATP in assay buffer (25 mM KCl, 12.5 mM
HEPES pH 7.9, 5 mM Mg acetate, 0. 25 mM DTT, 0.1% Triton
X-100) for 5 min at room temperature and in the presence of
Figure 1. Substructures and novel inhibitors. A) The core 4,5-dihydroxynaphthalene-2,7-disulfonate scaffold of three previously identified
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varying concentrations of the potential inhibitors. The extent of
protein adenylylation (and therefore competition with ATP for
binding to the active site) was subsequently measured by SDS/
PAGE and phosphorimaging. All reactions were done in at least
triplicate, and IC50 values were calculated using the GraphPad
Prism 5 software.
T. brucei Viability Assay
The effect of the identified REL1 inhibitors on parasite growth
was determined using the Alamar Blue assay, essentially as
described by Ra¨z et al. [31]. Briefly, T. brucei brucei cells (strain
s427) were seeded in 96-well plates at a density of 16104 cells per
ml in a volume of 200 ml, in the presence of varying concentrations
of predicted inhibitors or DMSO alone. After 48 hours, 20 ml
Alamar Blue (Invitrogen) were added to the cells and incubation
continued for an additional 24 hours. Absorbances at 540 and
595 nm were measured using an ELx808 Microplate Reader
(BioTek), and EC50 values were calculated using the GraphPad
Prism 5 software.
Results and Discussion
RNA editing ligase 1 (REL1) is a key component of the
trypanosomatid editosome. In trypanosomatid parasites (i.e.
species of Trypanosoma and Leishmania), mitochondrial mRNA
requires editing following transcription; after each round of U
addition or deletion, REL1 and the related protein REL2 religate
the RNA in an ATP-dependent reaction. REL1 is a noteworthy
drug target because it is required for the survival of T. brucei
[12,32] and presumably other trypanosomatids as well. Addition-
ally, no close human homologues have been identified [14]. The
heavy disease burdens caused by human African trypanosomiasis
(HAT), Chagas disease, and leishmaniasis, as well as the urgent
need for novel trypanocidal therapeutics and the success of virtual
screening against TbREL1 in the past, have motivated the current
work, wherein we identify novel TbREL1 inhibitors with
naphthalene-based scaffolds.
Similarity Search
Previously, Amaro et. al identified several micromolar inhibitors
of TbREL1 [14]. The top three inhibitors identified were all based
on a naphthalene-2,7-disulfonate (NDS) scaffold. In silico docking
provides insight into why this scaffold is amenable to TbREL1
inhibition (Figure 2). Similar to the adenine moiety of ATP (the
native co-factor), the NDS naphthalene group is able to form p-p
stacking interactions with F209. Additionally, one of the negatively
charged NDS sulfonate groups interacts electrostatically with the
positively charged R111 guanidino group at the active-site
periphery; R111 also participates in electrostatic and hydrogen-
bond interactions with the ATP polyphosphate tail. A hydrogen
bond is formed between NDS and N92, similar to the hydrogen
bond formed with the O2’ oxygen atom of the ATP ribose. Finally,
docking suggests that the second of the two NDS sulfonate groups
is buried deep within the binding pocket, displacing a water
molecule that normally mediates a hydrogen-bond network
between the ATP adenine N1 atom and R288. This water
displacement allows the sulfonate group to interact with the
charged R288 residue directly.
Unfortunately, these previously identified TbREL1 inhibitors
were ineffective against whole-cell T. brucei, likely because they are
too hydrophilic to cross lipid membranes (A. Schnaufer,
unpublished work). Interestingly, these compounds show similar-
ities to the anti-trypanosomal drug suramin, which, although
much larger, also has a negatively charged polysulfonated naphtyl
group [14]. How suramin enters the cell is unclear, but both fluid-
phase endocytosis and receptor-mediated uptake have been
Figure 2. TbREL1 binding. Solid black lines represent hydrogen bonds. Positively charged residues and ions (Mg2+) at the active-site periphery are
highlighted in yellow. The carbons of the F209 phenyl ring are shown in licorice. Portions of the protein are not visualized to improve clarity. A) ATP
binding. B) The predicted binding pose of naphthalene-2,7-disulfonate.
doi:10.1371/journal.pntd.0000803.g002
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suggested [33,34]. Suramin both binds various serum proteins,
which may facilitate uptake by the trypanosome cell [34], –and
inhibits a considerable number of enzymes, including dehydroge-
nases and kinases in various organisms and glycolytic enzymes
in T. brucei [35]. This promiscuous binding may be in part
attributable to the negatively charged sulfonate groups [35].
Additionally, the hydrophilicity these sulfonates impart likely
impedes both suramin and the previously identified REL1
inhibitors from passively crossing inner cellular membranes to
reach organellar targets such as mitochondrial proteins.
In an attempt to identify additional naphthalene-based TbREL1
inhibitors with improved pharmacological properties, we searched
several online databases of commercially available compounds for
similar structures: naphthalene-2-sulfonic acid, 2-naphthoic acid,
and 2-nitronaphthalene (Figure 1). These searches identified 588
compounds: 61 compounds from Hit2Lead (Hit2Lead.com,
ChemBridge), 394 from the NCI/DTP Open Chemical Repos-
itory (dtp.cancer.gov), 87 from Sigma-Aldrich (sigmaaldrich.com),
and 46 from ZINC [15]. In all, the search identified 376
naphthalene-2-sulfonic acid compounds, 130 2-naphthoic acid
compounds, and 85 2-nitronaphthalene compounds.
Virtual Screen
Given its previous successful identification of TbREL1 inhibi-
tors, AutoDock 4.0 was utilized for docking. Although the
AutoDock scoring function sacrifices accuracy for speed as
compared to more rigorous methodologies such as thermodynam-
ic integration [17,36], single-step perturbation [37], and free
energy perturbation [38], AutoDock performs well [39] when
compared to other docking programs such as DOCK [40], FlexX
[41], and GOLD [42].
The 588 compounds identified through online substructure
searches were first docked into a 1.20-A˚ resolution crystal structure
of the catalytic domain of TbREL1 [16]. AutoDock placed 14% of
the naphthalene compounds in the expected pose (26% of the 2-
naphthoic acid compounds, 10% of the naphthalene-2-sulfonic
acid compounds, and 8% of the 2-nitronaphthalene compounds),
with the naphthalene portion of the ligand buried deep in the
ATP-binding pocket and the electronegative group at the two
position either interacting with R288 or with R111 at the active-
site periphery.
The preliminary docking to the TbREL1 crystal structure, while
useful for eliminating those structures that were grossly incom-
patible with the TbREL1 active site, did not account for full
protein flexibility. Aside from the inaccuracies inherent in docking
scoring functions themselves, docking accuracy decreases further
when protein and/or ligand flexibility are ignored. When a ligand
approaches a protein receptor in solution, it does not encounter a
single static protein conformation, but rather an ensemble of many
different conformations. Often, a given ligand may only bind to a
certain subset of all protein conformations sampled, depending in
part on the varied side-chain positions of active-site residues.
When multiple protein conformations are incorporated into a
virtual-screening protocol, the hit rate can drastically improve;
ligands that do not bind to the crystal structure may bind to other
related protein conformations. Screening against these other
conformations in principle reduces the false negative rate.
Of the top-ranked 100 binders from preliminary crystal-
structure screens, 45 shared significant structural similarity with
the most potent compound identified previously by Amaro et al.
[14]. In order to account for full protein-receptor flexibility, these
45 compounds, roughly corresponding to the top 7.5% of the
library, were docked into 33 protein receptor conformations
extracted from a MD simulation of TbREL1 [14] using QR
factorization [20]. The 45 ligands were then reranked by their
respective ensemble-average scores, and 12 of the top compounds
(Table S1) were subsequently tested experimentally.
Experimental Results
Prior to RNA ligation, a key TbREL1 lysine must first be
adenylylated. To measure the inhibition of this first step of the
reaction pathway, the formation of TbREL1-[32P]AMP was
monitored via SDS/PAGE and autoradiography in the presence of
predicted inhibitor. Triton X-100 (0.1%) was added in order to
prevent aggregate-based inhibition. Four compounds, V1, (E)-7-
benzamido-4-hydroxy-3-((5-hydroxy-7-sulfonaphthalen-2-yl)diaze-
nyl)naphthalene-2-sulfonic acid; V2, (E)-7-amino-4-hydroxy-3-((5-
hydroxy-7-sulfonaphthalen-2-yl)diazenyl)naphthalene-2-sulfonic ac-
id; V3 (Di-J acid); and V4 (Mordant Black 25), inhibited TbREL1
activity with IC50 values of 2.1661.20 mM, 1.5361.17 mM, 8.366
1.71 mM, and 1.5961.1 mM, respectively (Table 1, Figure 1).
Additional information about the predicted binding poses of these
four validated inhibitors can be found in Table S1. An additional
four compounds inhibited TbREL1 adenylylation with IC50 values
between 10 and 100 mM; the exact values in these cases were not
determined (Table S1). All other compounds did not show significant
inhibition at 100 mM.
Binding to the Crystal-Structure Protein Conformation
May Be Suboptimal
Interestingly, the crystal-structure protein conformation used for
the initial docking is likely itself suboptimal for the binding of the
Table 1. A summary of the computational and experimental
results.
V1 V2 V3 V4
IC50 2.1661.20 1.5361.17 8.3661.71 1.5961.10
EC50 .100 .100 .100 2.1660.25
AutoDockCrystal 211.8 211.3 210.7 211.8
RankCrystal 11 20 31 25
AutoDockEnsemble 211.961.4 211.961.4 210.261.0 212.861.6
RankEnsemble 4 3 12 1
% Expected Pose 33% 33% 24% 18%
AutoDockEnsemble/
Expected
213.361.2 212.661.1 211.660.5 214.960.6
AutoDockEnsemble/
Unexpected
211.260.9 211.661.4 29.860.6 212.361.4
AutoDockEnsemble/Best 215.3 213.9 212.1 215.6
IC50 and EC50 are measures (in mM) of the inhibition of REL1 activity and parasite
growth, respectively; AutoDockCrystal is the predicted binding energy, in kcal/
mol, to the crystal structure; RankCrystal is the rank of the ligand when all 588
compounds are ordered by their respective AutoDockCrystal values;
AutoDockEnsemble is the average predicted binding energy to the 33
representative protein-receptor conformations obtained via QR factorization,
plus or minus the standard deviation; RankEnsemble is the rank of the ligand
when the top 45 compounds are ordered by their respective AutoDockEnsemble
values; % Expected Pose is the percentage of the 33 representative protein
structures amenable to deep-pocket binding, in which the naphthalene core is
docked deep into the binding pocket; AutoDockEnsemble/Expected is the average
predicted binding energy when only those members of the ensemble
amenable to deep-pocket binding are considered; AutoDockEnsemble/Unexpected is
the average predicted binding energy when only the remaining members of
the ensemble are considered; and AutoDockEnsemble/Best is the predicted
binding energy of the ligand to the ‘‘optimal protein conformation’’ from the
ensemble. All predicted energies are in kcal/mol.
doi:10.1371/journal.pntd.0000803.t001
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four inhibitors identified, as evidenced by the improvement in rank
when an ensemble-average AutoDock score was used (RankEnsemble)
instead of the crystal-structure score (RankCrystal, Table 1). In fact,
only one of the four compounds, V1, scored in the top twelve when
all 588 compounds were docked into the crystal structure alone. V2,
V3, and V4, which ranked 20th, 31st, and 25th against the crystal
structure, respectively, may not have been tested had the ligand set
not been reranked by an ensemble-average AutoDock score. A
direct comparison of the predicted binding energy of the four
indentified inhibitors docked into the crystal structure (AutoDock-
Crystal) and docked into the optimal protein conformation from the
ensemble (AutoDockEnsemble/Best) likewise demonstrates the impor-
tance of accounting for full protein flexibility; in all four cases,
predicted energies of binding improved several kcal per mol when
the optimal structure was used rather than the crystal structure
(Table 1).
In order to investigate why binding to the crystal structure was
suboptimal, the crystal structure was compared to the optimal
receptor conformation for each of the four ligands. By aligning the
best-scoring MD-generated receptor structures to the crystal
structure and visualizing both proteins and ligands, it is evident
that in all four cases the crystallographic position of E60 prevented
optimal binding. During the molecular dynamics simulation,
however, E60 extends its contact with R111 (initial contact
distance 5.35 A˚; final interaction distance greater than 11 A˚). This
movement opens a wide cleft that is favorably occupied by all four
of the novel inhibitors (Figure 3). This unique binding mode,
described in more detail below, would not have been identified
had protein-receptor flexibility been ignored.
RMSD Clustering Provides a Population-Based Structural
Analysis
To further explore the role that receptor flexibility plays in
inhibitor binding, we grouped the frames of the MD trajectory
into sets of geometrically similar conformations using an RMSD-
based clustering algorithm. Each cluster contains a central
structure, or centroid, whose structural characteristics and binding
properties are representative of all cluster members. Similar to QR
factorization [14,20], RMSD clustering reduces the MD ensemble
to a representative set of (centroid) conformations. However,
unlike QR factorization, RMSD clustering provides an approx-
imate idea of the probability of sampling a set of geometrically
similar conformations based on the fraction of conformations
contained within each cluster [21].
Assuming the conformations sampled along the inhibitor-bound
trajectories are similar to those observed during the ATP-bound
trajectory, the receptor-inhibitor interactions characteristic of the
most populated clusters, which represent the most frequently
visited system conformations, should contribute most to ligand
affinity. Indeed, the representative protein structure that best
accommodates V1, V3, and V4 from the QR-factorization
ensemble, as judged by the AutoDock score, belongs to the most
populated RMSD-based cluster. The protein conformation that
best accommodates V2 belongs to the second most populated
RMSD-based cluster.
The conformations sampled by the MD trajectory were grouped
into 8 clusters when an RMSD similarity cutoff of 0.085 A˚ was
used; 93.5% of the trajectory conformations were contained in the
three most populated clusters. The conformational variability
among the centroids of the top three clusters suggests two
dynamically distinct active-site regions. Deep within the inhibitor-
binding cleft, where F209 forms p-p stacking interactions with the
sulfonated naphthalene moiety of each inhibitor, the conforma-
tional differences among the centroids are modest, consisting of
only subtle amino-acid side-chain shifts (Figure 4A). Given the
rigidity of this region and the similarity between naphthalene and
the adenosine of ATP, the native TbREL1 substrate, we
hypothesize that the naphthalene scaffold is highly complimentary
to the modest conformational fluctuations observed at the deep
end of the binding pocket.
In contrast, conformational variability at the binding-site
periphery near the solvent interface is much larger (Figure 4B).
As the predicted binding modes of the validated inhibitors initially
suggested, the varied positions of E60 relative to R111 are
particularly notable. In the centroid conformation of the first and
second most populated clusters, a cleft is again seen between E60,
which is directed into bulk solvent, and R111, which is directed
toward the inhibitor binding site. The distances between
E60(OE2) and R111(NH1) are 9.01 A˚ and 10.96 A˚, respectively.
These two open-cleft clusters represent 83% of the entire
trajectory. In the centroid conformation of the third most
populated cluster, representing 11% of the entire trajectory, the
cleft is narrowed; E60 is directed downward, toward R111, and
the distance between E60(OE2) and R111(NH1) is only 7.14 A˚,
closer to the closed-cleft crystal-structure distance of 5.35 A˚. As
noted previously, all four novel inhibitors are predicted to occupy
this previously uncharacterized cleft, suggesting that it is
pharmacologically important.
This new cleft also presents an opportunity to develop com-
pounds with improved specificity over the related human DNA
ligases. A structural and sequence alignment of the superfamily
members [18] reveals key sequence differences in relative positions
between REL1 and human DNA ligase (PDB: 1X9N). In REL1,
residues I59-E60-I61-D62 line the newly revealed cleft and make
contact with several of the bound inhibitors. In human DNA ligase
1 (PDB 1X9N), the equivalent residues are M543-L544-A545-
H546. The strategic design of REL1 inhibitors to take advantage
of the variable contacts in this area, particularly the exposed side
chains of the residues lining the cleft, may present novel avenues to
design compounds with increased selectivity for the trypanosomal
enzymes.
Computational Fragment Mapping
To explore the pharmacological importance of the E60-R111
cleft in greater depth, computational fragment mapping was
carried out on both the centroids of the three most populated
clusters as well as the crystal structure (Figure 4C). Computational
fragment mapping estimates the binding affinity of fragment-sized
organic groups and clusters them into consensus-binding regions.
These consensus-binding regions (a.k.a. hot spots) represent
regions of receptor sites that are the principal contributors to the
ligand-binding energy. Importantly, these computationally pre-
dicted sites have been shown to correlate well with fragment-
binding hot spots as determined via biophysical experiments in
numerous studies [27,29,30].
Fragment mapping confirmed that the TbREL1 active site can be
divided into two regions, as two consensus sites were apparent. The
first site, conserved among the centroids of the three most populated
clusters as well as the crystal structure, is found deep in the inhibitor-
binding cleft, where both the adenine of the native ATP substrate
and the sulfonated-naphthalene moieties of the novel inhibitors
bind. The conservation of this solvent cluster supports the
pharmacological importance of this region and is in harmony with
the predicted docking poses of the four novel inhibitors.
The second consensus site is found in the previously
uncharacterized E60-R111 cleft. Notably, while conserved among
the three most populated clusters, this site is entirely absent in the
crystal structure, likely because the closed E60-R111 cleft of that
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structure occludes solvent-probe binding. Naphthalene-based
inhibitors docked into the crystal structure are predicted to interact
only with the high-affinity region deep in the binding pocket; at the
active-site periphery, binding to the high-affinity region in the E60-
R111 cleft is impossible, and so the predicted binding affinity is less
favorable. Hence, the fragment-mapping approach supports the
presence of an additional pharmacologically relevant feature of the
ATP binding pocket. It also helps to explain why those compounds
eventually confirmed as genuine inhibitors were not initially ranked
among the top-scoring candidates.
Figure 3. Predicted binding of the identified inhibitors to the respective optimal protein conformation from the ensemble. The
TbREL1 crystal structure is shown in mesh. The E60 and R111 residues of the optimal conformations are labeled directly, and the E60 residue of the
crystal structure is labeled with an arrow. In all four cases, the closed position of the crystal-structure E60 residue would have prevented optimal
ligand binding. A) V1. B) V2. C) V3. D) V4.
doi:10.1371/journal.pntd.0000803.g003
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While fragment mapping did reveal a high-affinity region in the
E60-R111 cleft of the centroid representing the third most
populated cluster, this region does not extend as far into the cleft
as the corresponding clusters of the top two centroids. This fact,
together with the narrower cleft width, may partly explain why
none of the four novel inhibitors was predicted to bind to receptor
conformations of the third most populated cluster.
Analysis of Predicted Binding Poses
In order to analyze the predicted binding mode of the four
confirmed TbREL1 inhibitors, the protein conformation from the
ensemble generated by QR-factorization that gave the best
AutoDock-predicted binding energy (i.e. the ‘‘optimal receptor’’)
was visualized together with the associated docked ligand. In all
cases, the electronegative group at the naphthalene C2 position
was buried deep within the active site, forming interactions with
R288, as expected. Additionally, three of the four ligands, similar
to the three most potent TbREL1 inhibitors identified previously
[14], had hydroxyl groups in the naphthalene 4 position,
suggesting that the hydrogen bonds formed with E86 and V88
are also critical to ligand binding (Figure S2, upper rows). A fourth
ligand, V4, had a hydroxyl group in the naphthalene 6 position,
were it could form hydrogen bonds with the backbone carbonyl
oxygen atom of V88 and the side-chain amino group of K87.
Figure 4. The centroids of the three most populated RMSD clusters aligned to the TbREL1 crystal structure. Coils are colored gray,
sheets are colored cyan, and helices are colored ice blue. A) Residues lining the deep end of the binding pocket used for RMSD clustering are shown
in a licorice graphical representation. Residues from the centroid of the first, second, and third most populated clusters are shown in red, blue, and
green, respectively. Residues from the crystal structure are shown in purple. B) E60 and R111 conformational variability. Coloring is as in A). The
orientation of E60 in the centroids of the top two most populated clusters differs from that of the third cluster, as well as from that of the crystal
structure. C) Consensus binding sites of the organic solvent probes used in the computational fragment mapping analysis. Solvent probe clusters are
colored to match the coloring in A) and B).
doi:10.1371/journal.pntd.0000803.g004
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At the active-site periphery, all four of the confirmed inhibitors
had secondary sulfonate groups that docked near the more
positively charged side of the active-site periphery, opposite the
R111 residue (Figure S3), where they interact with K307, R309,
and K87 (Figure S2, bottom rows). In contrast, the peripheral,
negatively charged sulfonate groups of previous NDS inhibitors,
substituents of the naphthalene core itself, interacted principally
with R111. The new inhibitors do not entirely neglect R111,
however; all four compounds are predicted to participate in p-
cation interactions with this residue.
In addition to these electrostatic interactions, the four novel
inhibitors are predicted to interact with other protein residues at
the active-site periphery (Figure S2, bottom rows). In some ways,
these interactions mimic the interactions between TbREL1 and its
native substrate, ATP. V1 forms a hydrogen bond with the R111
guanidinium group, similar to the bond formed between R111 and
the ATP gamma phosphate. V1 also forms a hydrogen bond with
the E159 side-chain carboxylate group, similar to the bond formed
with the ATP 29 ribose hydroxyl group. V1 forms unique
interactions with TbREL1 as compared to the substrate; V1 forms
a hydrogen bond with the backbone carbonyl of Y58, a residue
that does not participate in ATP binding (Figure S2A).
V2 is predicted to participate in only one hydrogen bond at the
active-site periphery. This bond is formed with the E60 side-chain
carboxylate group, a group that does not participate in ATP
binding (Figure S2B). V3 and V4 are likewise predicted to form
only one hydrogen bond at the active-site periphery, a bond with
the I59 backbone carbonyl. This same backbone carbonyl forms a
hydrogen bond with the 39 hydroxyl group of the ATP ribose
(Figure S2C).
Conclusion/Future Directions
Unfortunately, first-stage HAT treatments such as pentamidine
and suramin have harsh side effects [3], and second-stage
treatments such as melarsoprol can be fatal. The pharmaceutical
industry has been slow to develop novel trypanocidal therapeutics
because HAT infections occur primarily in developing countries
with little market appeal; indeed, the only novel trypanocidal
therapeutic registered in the last 50 years is eflornithine [43], a
drug that is likely only available because it can also be sold as a
topical cosmetic cream for the treatment of hirsutism in developed
countries.
Given the hesitancy of the pharmaceutical industry, in recent
years academia has played an increasing role in HAT drug-
discovery efforts (e.g. [44]). Amaro et al. recently identified
inhibitors based on a 4,5-dihydroxynaphthalene-2,7-disulfonate
scaffold that target T. brucei RNA editing ligase 1 (TbREL1), a
validated drug target in these organisms [12]. Unfortunately, these
inhibitors, while effective against the TbREL1 protein, were
ineffective in whole-cell assays. As Schrodinger’s LigPrep software
[45] suggested that at pH 7.0 the sulfonates of these compounds
are negatively charged, we hypothesize that they are too
hydrophilic to cross cellular and organellar T.-brucei lipid
membranes and thus cannot reach their physiological target.
The ALogP values of Amaro’s S5, V1, and S1 compounds were
21.043, 20.292, and 20.778, respectively (Discovery Studio,
Accelrys), likewise suggesting excessive hydrophilicity. Indeed, two
of these three compounds, S5 and S1, are too hydrophilic to be
considered druglike [46].
Building on the previous work of Amaro et al., we have
developed additional TbREL1 inhibitors based on novel naphtha-
lene scaffolds. The compounds proposed in the current work are
also sulfonated naphthalenes; however, some of them are more
hydrophobic than the naphthalene-based inhibitors identified
previously. The ALogP values of V1, V2, V3, and V4 are 0.492,
21.039, 21.112, and 1.835, respectively (Discovery Studio,
Accelrys), suggesting that two of the novel inhibitors, V1 and
V4, may even prefer a lipid environment. Indeed, V4 was effective
against cultured T. brucei with an EC50 of 2.16 mM (Table 1). To
what extent this trypanocidal effect can be attributed to inhibition
of REL1 is currently under investigation.
The hydrophobicity and specificity of these compounds, and
their ability to reach the mitochondrial matrix, could be further
improved by eliminating the charged sulfonate groups. In the
virtual screen presented here, naphthalenes with carboxylic acids
and nitro groups were included to see if the sulfonate groups could
be replaced with less electronegative functional groups. Unfortu-
nately, none of the compounds with carboxylate groups scored
well enough to justify experimental testing, and the few nitro-
group containing compounds that were tested failed to inhibit
TbREL1. Rather than replacing the sulfonate groups, a better
strategy may therefore be to modify those groups in order to
neutralize their charge. For example, replacing the sulfonate
groups with sulfonamides, a similar functional group that is not
charged, may decrease hydrophilicity while preserving important
protein-ligand interactions.
Both molecular docking and computational fragment mapping
indicate that a new cleft revealed by the molecular dynamics
simulations may play a role in the favorable binding of these four
novel TbREL1 inhibitors. Furthermore, RMSD-based clustering
indicated that this previously uncharacterized cleft persists for a
majority of the MD trajectory.
In the future, further drug optimization is needed. Three of the
four novel compounds contain diazene linkers that may be
hydrolysable in vivo. Furthermore, the nitrogen atoms of these
linkers are not predicted to participate in hydrogen bonds with the
protein; replacing one or both of them with carbon atoms may
therefore decrease hydrophilicity without sacrificing compound
potency. Additionally, some of the compounds contain other
moieties like hydroxyl and amino groups that are not predicted to
contribute to inhibitor binding. Perhaps these groups could
likewise be eliminated.
Supporting Information
Figure S1 The sixteen fragments used in the computational
fragment mapping.
Found at: doi:10.1371/journal.pntd.0000803.s001 (8.66 MB TIF)
Figure S2 TbREL1 binding. The top rows show binding deep
within the active site, and the bottom rows show binding at the
active-site periphery. Solid black lines represent hydrogen bonds.
Electropositive residues at the active-site periphery are highlighted
in yellow. The carbons of the F209 phenyl ring are shown in
licorice. Portions of the protein were removed to improve clarity.
A) The predicted binding pose of V1. B) The predicted binding
pose of V2. C) The predicted binding pose of V3. D) The
predicted binding pose of V4.
Found at: doi:10.1371/journal.pntd.0000803.s002 (7.23 MB TIF)
Figure S3 The TbREL1 active-site periphery. Positively charged
residues are highlighted in yellow. A) The predicted position of the
NDS peripheral sulfonate. B) The predicted position of the
peripheral sulfonates of V1, V2, V3, and V4.
Found at: doi:10.1371/journal.pntd.0000803.s003 (8.61 MB TIF)
Table S1 The twelve compounds that were tested experimentally.
Found at: doi:10.1371/journal.pntd.0000803.s004 (0.20 MB
DOC)
Novel TbREL1 Inhibitors
www.plosntds.org 9 August 2010 | Volume 4 | Issue 8 | e803
Acknowledgments
Non-financial support from the National Center for Supercomputing
Applications, the San Diego Supercomputer Center, the W.M. Keck
Foundation, the National Biomedical Computation Resource, the Center
for Theoretical Biological Physics, and the laboratory of J. Andrew
McCammon is gratefully acknowledged. We thank the NCI/DTP Open
Chemical Repository for providing compounds free of charge. We would
also like to thank Matthew G. Durrant for help with writing and figure
preparation.
Author Contributions
Conceived and designed the experiments: JDD RVS AS REA. Performed
the experiments: JDD LH RVS ML AS REA. Analyzed the data: JDD LH
RVS AS REA. Contributed reagents/materials/analysis tools: JDD ML
RVS AS REA. Wrote the paper: JDD RVS ML AS REA.
References
1. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007)
Control of neglected tropical diseases. N Engl J Med 357: 1018–1027.
2. Stich A, Abel PM, Krishna S (2002) Human African trypanosomiasis. BMJ 325:
203–206.
3. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, et al. (2002)
Treatment of human African trypanosomiasis–present situation and needs for
research and development. Lancet Infect Dis 2: 437–440.
4. WHO (2006) The World Health Organisation: African trypanosomiasis, Fact
sheet No. 259. Geneva: WHO publications.
5. Burri C, Keiser J (2001) Pharmacokinetic investigations in patients from
northern Angola refractory to melarsoprol treatment. Tropical medicine &
international health: TM & IH 6: 412–420.
6. Smith DH, Pepin J, Stich AH (1998) Human African trypanosomiasis: an
emerging public health crisis. Br Med Bull 54: 341–355.
7. Lukes J, Hashimi H, Zikova A (2005) Unexplained complexity of the
mitochondrial genome and transcriptome in kinetoplastid flagellates. Curr
Genet 48: 277–299.
8. Stuart KD, Schnaufer A, Ernst NL, Panigrahi AK (2005) Complex
management: RNA editing in trypanosomes. Trends Biochem Sci 30: 97–105.
9. Simpson L, Sbicego S, Aphasizhev R (2003) Uridine insertion/deletion RNA
editing in trypanosome mitochondria: a complex business. RNA (New York,
NY) 9: 265–276.
10. McManus MT, Shimamura M, Grams J, Hajduk SL (2001) Identification of
candidate mitochondrial RNA editing ligases from Trypanosoma brucei. RNA
7: 167–175.
11. Swift RV, Durrant J, Amaro RE, McCammon JA (2009) Toward understanding
the conformational dynamics of RNA ligation. Biochemistry 48: 709–719.
12. Schnaufer A, Panigrahi AK, Panicucci B, Igo RP, Jr., Salavati R, et al. (2001) An
RNA Ligase Essential for RNA Editing and Survival of the Bloodstream Form of
Trypanosoma brucei. Science 291: 2159–2162.
13. Amaro RE, Baron R, McCammon JA (2008) An improved relaxed complex
scheme for receptor flexibility in computer-aided drug design. J Comput-Aided
Mol Des 22: 693–705.
14. Amaro RE, Schnaufer A, Interthal H, Hol W, Stuart KD, et al. (2008) Discovery
of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei.
Proc Natl Acad Sci 105: 17278–17283.
15. Irwin JJ, Shoichet BK (2005) ZINC–a free database of commercially available
compounds for virtual screening. J Chem Inf Model 45: 177–182.
16. Deng J, Schnaufer A, Salavati R, Stuart KD, Hol WG (2004) High resolution
crystal structure of a key editosome enzyme from Trypanosoma brucei: RNA
editing ligase 1. J Mol Biol 343: 601–613.
17. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998)
Automated docking using a Lamarckian genetic algorithm and an empirical
binding free energy function. J Comput Chem 19: 1639–1662.
18. Amaro RE, Swift RV, McCammon JA (2007) Functional and Structural Insights
Revealed by Molecular Dynamics Simulations of an Essential RNA Editing
Ligase in Trypanosoma brucei. PLoS Negl Trop Dis 1: e68.
19. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable
molecular dynamics with NAMD. J Comput Chem 26: 1781–1802.
20. O’Donoghue P, Luthey-Schulten Z (2003) On the evolution of structure in
aminoacyl-tRNA synthetases. Microbiol Mol Biol Rev 67: 550–573.
21. Daura X, van Gunsteren WF, Mark AE (1999) Folding-unfolding thermody-
namics of a beta-heptapeptide from equilibrium simulations. Proteins 34:
269–280.
22. Landon MR, Amaro RE, Baron R, Ngan CH, Ozonoff D, et al. (2008) Novel
druggable hot spots in avian influenza neuraminidase H5N1 revealed by
computational solvent mapping of a reduced and representative receptor
ensemble. Chem Biol Drug Des 71: 106–116.
23. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, et al. (2008) Ensemble-
based virtual screening reveals potential novel antiviral compounds for avian
influenza neuraminidase. J Med Chem 51: 3878–3894.
24. Christen M, Hunenberger PH, Bakowies D, Baron R, Burgi R, et al. (2005) The
GROMOS software for biomolecular simulation: GROMOS05. J Comput
Chem 26: 1719–1751.
25. Shuman S, Lima CD (2004) The polynucleotide ligase and RNA capping
enzyme superfamily of covalent nucleotidyltransferases. Curr Opin Struct Biol
14: 757–764.
26. Swift RV, Amaro RE (2009) Discovery and design of DNA and RNA ligase
inhibitors in infectious microorganisms. Expert Opin Drug Discov 4:
1281–1294.
27. Brenke R, Kozakov D, Chuang GY, Beglov D, Hall D, et al. (2009) Fragment-
based identification of druggable ‘hot spots’ of proteins using Fourier domain
correlation techniques. Bioinformatics 25: 621–627.
28. Kortvelyesi T, Dennis S, Silberstein M, Brown L, 3rd, Vajda S (2003)
Algorithms for computational solvent mapping of proteins. Proteins 51:
340–351.
29. Landon MR, Lieberman RL, Hoang QQ, Ju S, Caaveiro JM, et al. (2009)
Detection of ligand binding hot spots on protein surfaces via fragment-based
methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des
23: 491–500.
30. Landon MR, Lancia DR, Jr., Yu J, Thiel SC, Vajda S (2007) Identification of
hot spots within druggable binding regions by computational solvent mapping of
proteins. J Med Chem 50: 1231–1240.
31. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R (1997) The Alamar Blue
assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense
and T.b. gambiense) in vitro. Acta Trop 68: 139–147.
32. Rusche LN, Huang CE, Piller KJ, Hemann M, Wirtz E, et al. (2001) The two
RNA ligases of the Trypanosoma brucei RNA editing complex: cloning the
essential band IV gene and identifying the band V gene. Mol Cell Biol 21:
979–989.
33. Fairlamb AH, Bowman IB (1980) Uptake of the trypanocidal drug suramin by
bloodstream forms of Trypanosoma brucei and its effect on respiration and
growth rate in vivo. Mol Biochem Parasitol 1: 315–333.
34. Vansterkenburg EL, Coppens I, Wilting J, Bos OJ, Fischer MJ, et al. (1993) The
uptake of the trypanocidal drug suramin in combination with low-density
lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop
54: 237–250.
35. Wang CC (1995) Molecular mechanisms and therapeutic approaches to the
treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 35:
93–127.
36. Oostenbrink BC, Pitera JW, van Lipzig MM, Meerman JH, van Gunsteren WF
(2000) Simulations of the estrogen receptor ligand-binding domain: affinity of
natural ligands and xenoestrogens. J Med Chem 43: 4594–4605.
37. Oostenbrink C, van Gunsteren WF (2004) Free energies of binding of
polychlorinated biphenyls to the estrogen receptor from a single simulation.
Proteins 54: 237–246.
38. Kim JT, Hamilton AD, Bailey CM, Domaoal RA, Wang L, et al. (2006) FEP-
guided selection of bicyclic heterocycles in lead optimization for non-nucleoside
inhibitors of HIV-1 reverse transcriptase. J Am Chem Soc 128: 15372–15373.
39. Bursulaya BD, Totrov M, Abagyan R, Brooks CL, 3rd (2003) Comparative
study of several algorithms for flexible ligand docking. J Comput Aided Mol Des
17: 755–763.
40. Ewing TJ, Makino S, Skillman AG, Kuntz ID (2001) DOCK 4.0: search
strategies for automated molecular docking of flexible molecule databases.
J Comput-Aided Mol Des 15: 411–428.
41. Rarey M, Kramer B, Lengauer T, Klebe G (1996) A fast flexible docking
method using an incremental construction algorithm. J Mol Biol 261: 470.
42. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and
validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727–748.
43. Barrett MP, Boykin DW, Brun R, Tidwell RR (2007) Human African
trypanosomiasis: pharmacological re-engagement with a neglected disease.
Br J Pharmacol 152: 1155–1171.
44. Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, et al. N-
myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature
464: 728–732.
45. (2009) LigPrep. 2,3 ed. New York, NY: Schrodinger, LLC.
46. Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based
approach in designing combinatorial or medicinal chemistry libraries for drug
discovery. 1. A qualitative and quantitative characterization of known drug
databases. J Comb Chem 1: 55–68.
Novel TbREL1 Inhibitors
www.plosntds.org 10 August 2010 | Volume 4 | Issue 8 | e803
